DexCom, Inc. (NASDAQ:DXCM) Stock Has Average Target Price of $89.08 According to Brokerages

DexCom, Inc. (NASDAQ:DXCM) has earned an average recommendation of “Moderate Buy” from the twenty-five analysts that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $89.08.

Several brokerages recently issued reports on DXCM. Truist Financial set a $102.00 price target on shares of DexCom and gave the company a “buy” rating in a research report on Friday, September 18th. Stifel Nicolaus set a $95.00 price objective on shares of DexCom and gave the stock a “buy” rating in a report on Friday, July 31st. Mizuho lifted their price objective on DexCom from $90.00 to $95.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. JPMorgan Chase & Co. upped their target price on DexCom from $65.00 to $82.00 and gave the stock a “neutral” rating in a report on Friday, July 31st. Finally, Wells Fargo & Company upped their target price on DexCom from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, July 31st.

Insider Activity at DexCom

In other DexCom news, EVP Michael Brown sold 1,700 shares of the firm’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $84.04, for a total transaction of $142,868.00. Following the completion of the transaction, the executive vice president owned 99,885 shares of the company’s stock, valued at approximately $8,394,335.40. This trade represents a 1.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nicholas Augustinos sold 6,539 shares of the business’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $84.04, for a total transaction of $549,537.56. Following the sale, the director owned 29,293 shares in the company, valued at approximately $2,461,783.72. This trade represents a 18.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 73,504 shares of company stock valued at $5,651,332 over the last ninety days. Insiders own 0.28% of the company’s stock.

Institutional Investors Weigh In On DexCom

Hedge funds have recently bought and sold shares of the business. Plato Investment Management Ltd bought a new position in shares of DexCom in the second quarter worth approximately $782,000. Aurora Investment Counsel purchased a new stake in shares of DexCom during the second quarter valued at approximately $2,340,000. E Fund Management Co. Ltd. bought a new stake in shares of DexCom during the second quarter valued at approximately $1,273,000. Silvant Capital Management LLC purchased a new position in DexCom in the 2nd quarter worth approximately $5,359,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in DexCom in the 2nd quarter worth approximately $89,940,000. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Down 0.0%

Shares of NASDAQ:DXCM opened at $86.64 on Friday. DexCom has a 1 year low of $54.11 and a 1 year high of $92.59. The company has a market cap of $32.69 billion, a PE ratio of 34.25, a P/E/G ratio of 1.45 and a beta of 1.42. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. The stock’s 50-day moving average is $85.81 and its 200 day moving average is $74.17.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The business had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $1.29 billion. During the same quarter last year, the business posted $0.48 EPS. The business’s revenue was up 13.1% on a year-over-year basis. Sell-side analysts anticipate that DexCom will post 2.64 EPS for the current year.

About DexCom

DexCom, Inc (NASDAQ: DXCM) develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its technology uses a small wearable sensor to measure glucose levels continuously and transmit readings to a compatible receiver, smartphone or other connected device, helping users monitor glucose trends and make more informed treatment and lifestyle decisions.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 real-time CGM systems, as well as related software and digital health tools such as Dexcom Clarity for glucose data analysis and reporting.